Financials Modus Therapeutics Holding AB
Equities
MODTX
SE0015987904
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.08 SEK | +47.52% | +63.14% | +19.88% |
Valuation
Fiscal Period: December | 2021 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Capitalization 1 | 61.18 | 62.35 | 74.75 | - | - |
Enterprise Value (EV) 1 | 61.18 | 62.35 | 73.75 | 29.75 | 67.75 |
P/E ratio | - | -1.72 x | -4.16 x | -2.08 x | -1.96 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - |
EV / Revenue | - | - | - | - | - |
EV / EBITDA | -2.96 x | - | -4.1 x | -0.83 x | -1.78 x |
EV / FCF | - | - | -4.1 x | -0.83 x | -1.78 x |
FCF Yield | - | - | -24.4% | -121% | -56.1% |
Price to Book | - | - | -208 x | 1.7 x | 13 x |
Nbr of stocks (in thousands) | 16,100 | 35,939 | 35,939 | - | - |
Reference price 2 | 3.800 | 1.735 | 2.080 | 2.080 | 2.080 |
Announcement Date | 2/22/22 | 2/21/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net sales | 0.002 | - | - | - | - | - |
EBITDA 1 | - | -20.69 | - | -18 | -36 | -38 |
EBIT 1 | - | -20.69 | - | -18 | -36 | -38 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | - | - | -18 | -36 | -38 |
Net income 1 | -6.019 | - | -17.9 | -18 | -36 | -38 |
Net margin | -300,950% | - | - | - | - | - |
EPS 2 | - | - | -1.010 | -0.5000 | -1.000 | -1.060 |
Free Cash Flow 1 | - | - | - | -18 | -36 | -38 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 4/14/21 | 2/22/22 | 2/21/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | - | - | - | 1 | 45 | 7 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | - | -18 | -36 | -38 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share 2 | - | - | - | -0.0100 | 1.220 | 0.1600 |
Cash Flow per Share | - | - | - | - | - | - |
Capex | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 4/14/21 | 2/22/22 | 2/21/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+19.88% | 7.1M | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- MODTX Stock
- Financials Modus Therapeutics Holding AB